Qu'est-ce qu'un biosimilaire ? Jusqu'où va la similarité ?
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 183, doi. 10.1007/s10269-011-2020-1
- By:
- Publication type:
- Article
Works matching IS 12923818 AND DT 2011 AND VI 13 AND IP 5
Results: 13
1
2
QCM Biosimilaires.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 247, doi. 10.1007/s10269-011-2022-z
- Publication type:
- Article
3
Biosimilaires actuellement disponibles en hémato-oncologie Partie I: ASEs (agents stimulant l'érythropoïèse).
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 209, doi. 10.1007/s10269-011-2013-4
- By:
- Publication type:
- Article
4
Guidelines EMA pour le développement de médicaments biosimilaires.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 191, doi. 10.1007/s10269-011-2011-2
- By:
- Publication type:
- Article
5
Biosimilaires d'héparine de bas poids moléculaire: quel degré de similarité pour quel bénéfice clinique ?
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 239, doi. 10.1007/s10269-011-2012-1
- By:
- Publication type:
- Article
6
Biosimilaires : « Is absence of proof of difference, proof of absence of difference? ».
- Published in:
- 2011
- By:
- Publication type:
- Editorial
7
Les facteurs de croissance (CSF) biosimilaires : une avancée ?
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 201, doi. 10.1007/s10269-011-2019-7
- By:
- Publication type:
- Article
8
Market access of biosimilars: not only a cost issue.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 218, doi. 10.1007/s10269-011-2018-8
- By:
- Publication type:
- Article
9
What does a prescriber think of biosimilars?
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 234, doi. 10.1007/s10269-011-2015-y
- By:
- Publication type:
- Article
10
« Regards croisés 2009 »: enquête menée auprès de patients atteints de cancer et de professionnels de santé sur la perception de la fatigue et de l'anémie chimio-induite, typologies et enseignements.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 249, doi. 10.1007/s10269-011-2004-1
- By:
- Publication type:
- Article
11
Presently available biosimilars in hematology-oncology - Part II: G-CSF.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 213, doi. 10.1007/s10269-011-2014-z
- By:
- Publication type:
- Article
12
Risk management of biosimilars in oncology.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 196, doi. 10.1007/s10269-011-2016-x
- By:
- Publication type:
- Article
13
The economic pressures for biosimilar drug use in cancer medicine.
- Published in:
- Oncologie (Tech Science Press), 2011, v. 13, n. 5, p. 222, doi. 10.1007/s10269-011-2017-9
- By:
- Publication type:
- Article